{"version":"1.0","provider_name":"Tafalgie Therapeutics","provider_url":"https:\/\/tafalgie.fr\/fr\/","author_name":"Tafalgie_client_23","author_url":"https:\/\/tafalgie.fr\/fr\/author\/tafalgie_client_23\/","title":"Participation au programme \"IPOready 2024\" - Tafalgie Therapeutics","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"4XZoaSy0H3\"><a href=\"https:\/\/tafalgie.fr\/fr\/participer-au-programme-ipoready-2024\/\">Participation au programme \u00ab\u00a0IPOready 2024\u00a0\u00bb<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/tafalgie.fr\/fr\/participer-au-programme-ipoready-2024\/embed\/#?secret=4XZoaSy0H3\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Participation au programme \u00ab\u00a0IPOready 2024\u00a0\u00bb\u00a0\u00bb &#8212; Tafalgie Therapeutics\" data-secret=\"4XZoaSy0H3\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/tafalgie.fr\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"Tafalgie Therapeutics participera au programme pre-IPO \u2018IPOready\u2019 2024 organis\u00e9 par Euronext pour la 9\u00e8me ann\u00e9e cons\u00e9cutive Tafalgie Therapeutics, une soci\u00e9t\u00e9 de recherche biopharmaceutique sp\u00e9cialis\u00e9e dans la recherche et l\u2019innovation des traitements pour la pr\u00e9vention et le soulagement des douleurs aigu\u00ebs et chroniques (inflammatoires, postop\u00e9ratoires, neuropathiques) sans effets ind\u00e9sirables, est fi\u00e8re d\u2019annoncer qu\u2019elle a \u00e9t\u00e9 s\u00e9lectionn\u00e9e [&hellip;]","thumbnail_url":"https:\/\/tafalgie.fr\/wp-content\/uploads\/2024\/03\/AdobeStock_261523510-1024x683.jpeg"}